$280.03
+1.67(0.60%)
Mkt Cap $7.6B
$216.56
$339.75
52-Week Range
At a Glance
AI-generatedBio-Rad Laboratories, Inc.
Revenue breakdown: Clinical Diagnostics (58.7%), Life Science (41.3%), All Other Segments (0.1%).
8-K
Bio-Rad Laboratories, Inc. announced Q4 and full-year 2025 financial results with Q4 revenue of $693.2 million (up 3.9% YoY) and full-year revenue of $2,583.2 million (up 0.7% YoY), alongside non-GAAP operating margins and 2026 guidance for 0.5-1.5% currency neutral revenue growth. Results reflect Clinical Diagnostics growth offset by Life Science declines due to funding constraints, with significant Sartorius AG investment gains driving GAAP net income.$7.6B
Market Cap
$2.6B
Revenue
$760M
Net Income
Employees7,700
Fundamentals
How The Business Makes Money
Revenue by Segment
Clinical Diagnostics58.7%($4.6B)
Life Science41.3%($3.2B)
All Other Segments0.1%($4M)
Revenue by Geography
US40.7%($3.2B)
Europe32.4%($2.5B)
Asia Pacific20.4%($1.6B)
Americas6.4%($501M)
Activity
What Changed Recently
Analyst View
Company Profile
CIK0000012208
ISINUS0905722072
CUSIP090572207
Phone510 724 7000
Address1000 Alfred Nobel Drive, Hercules, CA, 94547, US
SEC EDGAR